Hepatic Biomarkers Market Size - Forecasts to 2026

The findings reviewed by GME stated that the Global Non-invasive Prenatal Testing Market will expand with a CAGR value of 11.5 percent from 2021 to 2026. The rise in the prevalence of genetic diseases, rapid acceptance of next-generation testing, innovative product releases, and an increase in the number of non-invasive prenatal testing service providers are driving the non-invasive prenatal testing market.

Browse 159 Market Data Tables and 119 Figures spread through 189 Pages and in-depth TOC on "Global Non-invasive Prenatal Testing Market - Forecast to 2026"

https://www.globalmarketestimates.com/market-report/global-non-invasive-prenatal-testing-market-3045

By Gestation Period (0-12 Weeks, 13-24 Weeks, and 25-36 Weeks), By Risk Type (High & Average Risk and Low Risk), By Method (Ultrasound Detection, Biochemical Screening Tests, and Cell-Free DNA in Maternal Plasma Tests), By Technology (NGS, Array Technology, PCR, and Other Technologies), By Product (Consumables & Reagents and Instruments), By End-User (Hospitals & Clinics and Diagnostic Laboratories), By Region (North America, Asia Pacific, CSA, Europe, and the Middle East and Africa); End-User Landscape, Company Market Share Analysis & Competitor Analysis

Key Market Insights

The advancements in testing technology and the growth of bioinformatics are expected to increase the demand for non-invasive prenatal testing.
The largest share of the 13-24 weeks segment is mainly attributed to the fact that the majority of NIPT is performed during the second trimester, in conjunction with other tests.
The rising number of high-risk pregnancies among women over the age of 35 has resulted in the domination of the high and medium risk segments.
The largest share of cell-free DNA-based NIPT segment is mainly attributed to the ongoing technological advancements.
The NGS segment held the dominant share of the market among non-invasive prenatal testing technologies in 2020.
The rising prevalence of non-invasive prenatal testing focused on NGS technology has been a key driver of the consumables and reagents segment.
The diagnostic laboratories segment has the largest share owing to the high availability of advanced diagnostic instruments.
Natera, Inc., Illumina Inc., MedGenome Labs Ltd., Eurofins LifeCodexx GmbH, F. Hoffmann-La Roche Ltd., Centogene N.V., Genesis Genetics, Myriad Women’s Health Inc., Laboratory Corp. of America Holdings, Progenity Inc., Qiagen, Quest Diagnostics Inc., among others, are the major vendors competing in the Non-invasive Prenatal Testing market.

Browse the Report @ https://www.globalmarketestimates.com/market-report/global-non-invasive-prenatal-testing-market-3045

Gestation Period Outlook (Revenue, USD Billion, 2021-2026)